ClinicalTrials.gg
Active, not recruitingNCT07443982AMI-HOPEUpdated Mar 2, 2026

Acute Myocardial Infarction - Allied Health-Oriented Patient-centered Digitally-Enabled Care

An interventional study of Standard of Care (SOC) and Pharmacist-led digital platform assisted care in Acute Myocardial Infarction (AMI), sponsored by National University Heart Centre, Singapore. Active, not recruiting at 6 sites in Singapore. Open to participants aged 21 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-03-02.

Sponsored by National University Heart Centre, Singapore · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 years after the study started (first participant enrolled Jan 2023, registered Feb 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,633
Allocation
Randomized
Ages
21 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Myocardial Infarction with a site in Singapore — 2 open to participants now, 4 under way, 1 of them phase 3. Myocardial Infarction · Singapore.

Enrollment
5th of 14
1,633 · median 594
Started
2023
with 3 others
No phase
6 of 16
1 open now
Registered
16th of 16
by date
Lead sponsor
1 of 16
National University Heart Centre, Singapore

Among the 16 studies in Myocardial Infarction with a site in Singapore, this one is the 5th largest by enrollment of the 14 interventional ones that give a count, is one of 4 that started in 2023, is one of 6 with no phase, and was the 16th registered.

Myocardial Infarction

2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.

Browse Myocardial Infarction studies →

Open to participants now

2 of the 16 studies in Myocardial Infarction with a site in Singapore are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →

Who these studies take

Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.

This study: 21 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Myocardial Infarction with a site in Singapore, or all of them as a file.
02

Study summary

The Acute Myocardial Infarction - allied Health Oriented, Patient centered, and digitally Enabled care (AMI-HOPE) program is a model of care designed to improve post-AMI well-being, safety, and outcomes through greater involvement of AHPs in patient care and integrating digital technologies into routine primary care disease management. AMI-HOPE aims to deliver solutions to these identified gaps of care which will transform healthcare planning both at cluster and national levels. The cornerstone of the AMI-HOPE program will be upskilling pharmacists to take on low-intermediate complexity clinician roles during the post-discharge period. The first 6 months will be anchored by tertiary care before a handoff to primary care. This frees up cardiologists to focus on high complexity cases.

Read the detailed description

The AMI-HOPE program addresses three critical healthcare challenges: insufficient specialist capacity, limited outpatient clinic infrastructure, and excessive dependence on hospital-based rather than community-based care during the vulnerable early post-discharge period for myocardial infarction patients. The program trains pharmacists to provide comprehensive post-MI (Myocardial Infarction) care through personalized cardiovascular medication optimization, targeted interventions for patients with reduced ejection fraction, smoking cessation support, and lifestyle counseling covering diet and exercise. Care delivery occurs remotely through integrated digital health platforms that facilitate continuous vital signs monitoring, deliver structured patient education at strategic intervals, and promote effective self-management capabilities.

This proof-of-value stepped-wedge pragmatic trial that evaluates the effectiveness of the AMI-HOPE intervention is conducted across seven hospitals and eighteen primary care polyclinics spanning Singapore's three health clusters.

03

Conditions studied

  • Acute Myocardial Infarction (AMI)
04

Who can participate

Ages eligible
21 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or Female, aged 21 to 90 years (inclusive), at the time of signing the form
  • Clinically diagnosed with AMI during index hospitalisation
  • Own a mobile phone with internet access- intervention arm only

Exclusion criteria

Exclusion Criteria:

  • Patients who are planned for palliative care or \<1 year
  • Foreigners who do not have Singaporean citizenship/ Permanent Resident (PR) status
  • Patients who are enrolled into Healthier SG affiliated with General Practitioners (GPs)
  • Allergy or intolerance of Angiotensin-Converting Enzyme Inhibitors (ACE-I) or Angiotensin II Receptor Blockers (ARB)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,633 participants (actual)

Study arms

  • Other
    Control

    Standard of Care

    Other: Standard of Care (SOC)

  • Other
    Pharmacist-led digital platform assisted care

    AMI-HOPE centers around a digital platform that offers continuous telemonitoring on patients' vitals, tailored medication prescription with support from pharmacists, and personalised lifestyle nudges and educational material.

    Other: Pharmacist-led digital platform assisted care

Interventions

  • OtherStandard of Care (SOC)

    Standard of care treatment without the pharmacist-led digital platform assisted care

  • OtherPharmacist-led digital platform assisted care

    Up titration of medications by pharmacist. AMI-HOPE centers around a digital platform that offers continuous telemonitoring on patients' vitals, tailored medication prescription with support from pharmacists and personalised lifestyle nudges and educational material.

06

What researchers measure

Primary outcomes

  1. Death and Unplanned Cardiovascular Disease (CVD) related (non-fatal MI, non-fatal stroke, others) rehospitalizations

    Counts and time to any events of death or unplanned CVD related rehospitalizations

    Time frame: between enrolment and end of 12-month follow up

Secondary outcomes

  1. Absolute change in concentration of Low-Density Lipoprotein Cholesterol (LDL-C)

    Absolute change in LDL-C (in mmol/L) from enrollment to end of 12 month follow up period

    Time frame: between enrolment and end of 12-month follow up

  2. Change in Blood Pressure (BP)

    Absolute change in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) (in mmHg) from enrollment to end of 12 month follow up period

    Time frame: At discharge, 2 week, 1, 3, 6, 9 &12 months

  3. Change in Haemoglobin A1c (HbA1c)

    Absolute change in HbA1c (in %) from enrollment to end of 12 month follow up period

    Time frame: between enrolment and end of 12-month follow up

  4. EuroQoL (Quality of Life)-5 Dimensions (EQ-5D) Scores in Participants

    EQ-5D was calculated to evaluate quality of life (QoL) in participants. EQ-5D is a participant answered questionnaire scoring 5 dimensions - mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The EQ-5D total score ranges from 0 (worst health state) to 1 (perfect health state) and 1 reflects the best outcome.

    Time frame: At 1 month and 12 month

  5. Patient Activation Measure (PAM-13) Scores in Participants

    The Patient Activation Measure 13 (PAM-13) is a non-disease-specific survey that assesses a patient's knowledge, skills, and confidence for self-management. It uses 13 items on a 4-point Likert scale, with the raw sum score (ranging from 13-52) being transformed into a standardized 0-100 metric.

    Time frame: At discharge and 6month

  6. Seattle Angina Questionnaire-7 (SAQ-7) Scores in Participants

    The change from baseline in Health-Related Quality of Life (HRQOL) is assessed by the SAQ-7. The SAQ-7 is a validated tool assessing three domains: physical limitation, angina frequency, and quality of life. An overall summary score is calculated by averaging the three domain scores (0-100), where higher scores indicate better health status (i.e., less frequent angina, better function, and higher quality of life).

    Time frame: At 1 month and 12 month

  7. Patient Health Questionnaire-9 (PHQ-9) Scores in Participants

    The PHQ-9 is a validated 9-item self-report instrument used for screening and assessing the severity of depression. Each item is scored from 0 ("not at all") to 3 ("nearly every day") based on symptom frequency over the past two weeks, yielding a total score from 0 to 27, with higher scores indicating greater depression severity.

    Time frame: At 1month and 12 month

  8. Presence of angina pectoris as determined by the Rose Angina Questionnaire

    The Rose Angina Questionnaire is a standardized, validated set of questions used to identify the presence of angina pectoris in epidemiological studies. It consists of a structured interview algorithm that classifies participants based on their responses to questions about chest pain characteristics, leading to a categorical outcome (e.g., definite angina, possible angina, or no angina).

    Time frame: At 1month and 12month

  9. Dose of ACE/ARB/MRA inhibitor

    Change in drug intensity score for ACE inhibitors/angiotensin receptor blockers/angiotensin receptor-neprilysin inhibitors (ACE I/ARB/ARNI) and beta blockers, to assess the effect of the pharmacist led intervention on prescription, early up titration, and adherence to drugs, and the subsequent impact on LDL C, blood pressure, HbA1c control, and left ventricular ejection fraction (LVEF).

    Time frame: At discharge, 1, 3, 6 &12 months

  10. Percentage of patients smoking

    Each patient would be asked to indicate whether they are currently an active smoker(yes/no) at each point of assessment (at 1,3, 6 \& 12 month). The change in percentage of active smoker in the duration of the programme is use to assess the effectiveness of the smoking cessation programme.

    Time frame: At 1,3, 6 & 12 month

  11. Length of stay

    To assess the clinical efficiency of the intervention

    Time frame: Baseline

Other outcomes

  1. Cost-effectiveness

    Health benefits expressed in Quality-Adjusted Life Years (QALYs) and incremental cost-effectiveness ratio (ICER) as the incremental cost of intervention delivery divided by the incremental health outcome (QALYs gained), to assess cost-effectiveness

    Time frame: At the end of 12-month follow up

07

Study locations

6 sites
08

References and documents

Publications

  • Wang M, Lim ZZ, Chan SP, Teo ZL, Tan SH, Panday V, Sze HJ, Wong YM, Chang G, Ng F, Syed I, Lim P, Huang Z, Lim Z, Teo V, Phoon I, Kunarso G, Chai SC, Siau KR, Kwan YS, Ho S, Lim L, Sim M, Yap HR, Oh WL, Chong HP, Yeo A, Deorani P, Morris R, Ho HH, Hausenloy DJ, Wee HL, Tan D, Chan MY. Pharmacist-led, digitally enabled transitional care after acute myocardial infarction: design and baseline characteristics of the AMI-HOPE nationwide stepped-wedge trial. Eur Heart J Digit Health. 2026 Jun 20;7(6):ztag094. doi: 10.1093/ehjdh/ztag094. eCollection 2026 Jul. PubMed 42499410 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Sep 2026, 44 months after the start.

Of 322 non-industry interventional studies with no phase under Myocardial Infarction, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 58. This study's planned 44 months is above that.

Counting every sponsor, half of 355 studies reached it within 34 months; a quarter within 15 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2026
First posted
Mar 2, 2026
StartActual
Jan 11, 2023
Primary completionEst.
Sep 30, 2026
CompletionEst.
Sep 30, 2026
Last update
Mar 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07443982
Lead sponsor
National University Heart Centre, Singapore
Responsible party
Mark Chan (Deputy Executive Director and Senior Consultant, National University Heart Centre, National University Heart Centre, Singapore) — Principal investigator
First posted
Mar 2, 2026
Start date
Jan 11, 2023
Primary completion
Sep 30, 2026 (estimated)
Completion
Sep 30, 2026 (estimated)
Last update
Mar 2, 2026

Study contacts

Mark Chan
principal investigator · National University Heart Centre, Singapore

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion